Euglena Stock Forecast for 2023 - 2025 - 2030
Updated on 05/08/2024
Euglena Stock Forecast and Price Target
If the average 2024 price target of ¥1000.00 recently set by prominent experts for Euglena is met, there would be a potential upside of approximately 90.84% from the last closing price in May, 2024. The high estimate is ¥1000.00, and the low is ¥1000.00. If you're thinking of investing in 2931 stock, it's critical to check out its competitors as well.
90.84% Upside
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4568 Stock Forecast | Daiichi Sankyo Company | Buy |
4
|
¥5.32k | Buy/Sell | ¥5.24k | 8.94% |
| 4519 Stock Forecast | Chugai Pharmaceutical | Outperform |
6
|
¥4.99k | Buy/Sell | ¥4.92k | 23.37% |
| 4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
5
|
¥4.10k | Buy/Sell | ¥4.74k | 11.00% |
| 4503 Stock Forecast | Astellas Pharma | Outperform |
18
|
¥1.56k | Buy/Sell | ¥2.64k | 29.60% |
| 4507 Stock Forecast | Shionogi & | Outperform |
18
|
¥7.41k | Buy/Sell | ¥7.12k | 7.90% |
Euglena Revenue Forecast for 2023 - 2025 - 2030
In the last year, Euglena's Revenue has grown from ¥30.51B to ¥44.39B – a 45.50% increase. For the next year, 0 analysts project Euglena's Revenue to drop by 31.27%, reaching ¥30.51B. By 2030, professionals believe that Euglena's Revenue will decrease by 14.99%, reaching ¥37.74B – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4523 Stock Forecast | Eisai | Outperform |
18
|
¥6.60k | Buy/Sell | ¥9.58k | 27.37% |
| 4151 Stock Forecast | Kyowa Kirin | Outperform |
18
|
¥2.69k | Buy/Sell | ¥3.06k | 13.55% |
| 4528 Stock Forecast | Ono Pharmaceutical | Hold |
18
|
¥2.30k | Buy/Sell | ¥2.76k | 8.84% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4967 Stock Forecast | Kobayashi Pharmaceutical | Outperform |
18
|
¥6.61k | Buy/Sell | ¥8.86k | 33.07% |
| 4506 Stock Forecast | Sumitomo Pharma | Underperform |
18
|
¥464.00 | Buy/Sell | ¥0.00 | 5.82% |
| 4536 Stock Forecast | Santen Pharmaceutical | Outperform |
18
|
¥1.53k | Buy/Sell | ¥0.00 | 7.53% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4516 Stock Forecast | Nippon Shinyaku | Outperform |
18
|
¥4.39k | Buy/Sell | ¥8.34k | 48.20% |
| 4530 Stock Forecast | Hisamitsu Pharmaceutical | Hold |
16
|
¥3.77k | Buy/Sell | ¥5.00k | 4.89% |
| 4887 Stock Forecast | Sawai Group Holdings | Outperform |
16
|
¥5.70k | Buy/Sell | ¥5.90k | 22.85% |
Euglena EBITDA Forecast for 2023 - 2025 - 2030
In the last year, Euglena's EBITDA has seen a drop from ¥-4.45B to ¥-359.00M – a 91.93% decrease. In the next year, analysts believe that EBITDA will reach ¥-4.45B – an increase of 1138.50%. For the next eight years, the forecast is for EBITDA to grow by 16900.28%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4521 Stock Forecast | Kaken Pharmaceutical | Hold |
14
|
¥3.59k | Buy/Sell | ¥0.00 | -2.45% |
| 4553 Stock Forecast | Towa Pharmaceutical | Outperform |
18
|
¥2.62k | Buy/Sell | ¥0.00 | 18.46% |
| 4534 Stock Forecast | Mochida Pharmaceutical | Hold |
18
|
¥3.21k | Buy/Sell | ¥3.40k | -0.16% |
Euglena EBIT Forecast for 2023 - 2025 - 2030
In the last year, Euglena's EBIT has gone down from ¥-6.20B to ¥-3.53B – a 42.99% drop. In the next year, analysts believe that EBIT will reach ¥-6.20B – an increase of 75.41%. For the next eight years, experts predict that Euglena's EBIT will grow at a rate of 69.46%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4551 Stock Forecast | Torii Pharmaceutical | Outperform |
14
|
¥3.99k | Buy/Sell | ¥4.04k | 9.16% |
| 4547 Stock Forecast | Kissei Pharmaceutical | Hold |
16
|
¥3.32k | Buy/Sell | ¥0.00 | 2.41% |
| 4569 Stock Forecast | KYORIN Pharmaceutical | Underperform |
16
|
¥1.79k | Buy/Sell | ¥0.00 | -16.06% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4552 Stock Forecast | JCR Pharmaceuticals | Outperform |
18
|
¥806.00 | Buy/Sell | ¥1.84k | 86.10% |
| 4559 Stock Forecast | Zeria Pharmaceutical | Buy |
16
|
¥2.10k | Buy/Sell | ¥2.81k | 34.13% |
| 2929 Stock Forecast | Pharma Foods International | - |
17
|
¥1.07k | Buy/Sell | ¥0.00 | -100.00% |
.jpg)